BioCentury
ARTICLE | Company News

Nektar, University of Texas MD Anderson Cancer Center deal

June 22, 2015 7:00 AM UTC

Nektar and MD Anderson partnered to conduct a Phase I/II trial to evaluate NKTR-214 alone or in combination with other therapies, including PD-1 inhibitors, in a variety of tumor types. The trial is...